The Regenerative Medicine Alliance of Canada (RMAC) is a voluntary organization composed of national, provincial and regional organizations committed to building a robust regenerative medicine sector in Canada. Members work collaboratively to share information and identify strategies to bring innovative treatments and therapies out of the lab and into the clinic. Bolstering and aligning programs, training, policy and communication are central themes addressed by RMAC. All RMAC members have mandates relevant to stem cell research and/or regenerative medicine.
RMAC founding members:
adMare BioInnovations is Canada’s Global Life Sciences Venture, changing the landscape of the Canadian life sciences ecosystem from sea to sea. We do this by sourcing the most therapeutically and commercially promising research from leading academic and biotech partners to create new companies of scale, providing specialized expertise and infrastructure to help existing companies scale up, and driving the growth of those companies into Canadian anchors by training the next generation of highly-qualified personnel. Read more about adMare BioInnovations here.
The British Columbia Regenerative Medicine Initiative (BCRegMed) is funded by UBC’s Research Excellence Cluster program and partners to support the coalescence of academic, industry and government entities to foster collaborative activities within the BC regenerative medicine community. The network aims to engage and mobilize the scientific and entrepreneurial community in BC and the wider Cascadia region to facilitate the translation and commercialization of basic discoveries. Read more about BCREGMED here.
CellCAN is a pan-Canadian non-profit organization established in 2014 that is part of the Government of Canada’s Networks of Centers of Excellence. Our mission is to improve the quality, safety and feasibility of cell and gene therapy in Canada through optimal manufacturing practices. CellCAN strives to fully exploit this potential by providing an unprecedented level of collaboration among all key players in the field of cell and gene therapy by bringing together Canada’s leading cell manufacturing centers and transversal cores (manufacturing product characterization, bioengineering, ethical and legal regulatory policy) into a common seal of quality for the benefit of Canadian patients. Read more about CellCAN here.
CCRM is a Canadian, not-for-profit funded by the Government of Canada, the Province of Ontario, and leading academic and industry partners. It supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. CCRM has a 40,000 square foot space dedicated to advanced cell manufacturing that includes a Good Manufacturing Practices facility for producing cells and viral vectors. CCRM aims to accelerate the translation of scientific discovery into new companies and marketable products for patients. CCRM is the commercialization partner of OIRM and the University of Toronto’s Medicine by Design. Read more about CCRM here.
C3i provides an integrated structure to accelerate the discovery, development, commercialization and access to innovative cancer immunotherapies and regenerative medicine. One of the biounits represented by C3i is the Centre of Excellence for Cellular Therapy (CETC), a fully operational state-of-the art cGMP manufacturing facility for cellular therapies, including cancer immunotherapies. Located within the Hospital Maisonneuve-Rosemont in Montreal, the CETC facilities have been validated and met expectations for the Canadian, European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) regulatory agencies. The CETC has received the highest certification from the U.S. Foundation for the Accreditation of Cell Therapies (FACT) for “more than minimally manipulated cells” and is the largest operational Good Manufacturing Practices (GMP)-validated centre in Canada. Read more about C3i here.
Medicine by Design
Medicine by Design harnesses the exceptional expertise at the University of Toronto and its affiliated hospitals at the convergence of physical and life sciences, engineering, mathematics and medicine to undertake transformative research in regenerative medicine and cell therapy. It fosters unique multidisciplinary collaborations and uses engineering design principles and quantitative biological modelling to accelerate breakthroughs. Through strategic investments and partnerships, Medicine by Design is powering Toronto’s burgeoning biomedical ecosystem, strengthening Canada as a global centre for regenerative medicine and improving health outcomes. Read more about Medicine by Design here.
Ontario Institute for Regenerative Medicine
The Ontario Institute for Regenerative Medicine (OIRM) is a non-profit stem cell institute funded by the Ontario government and dedicated to transforming discoveries into clinical trials and cures. Through our commitment to collaboration and partnerships, we leverage our resources to fund and support promising advances. OIRM is a passionate champion for investigators and their patients as we build a healthier future for Ontario, Canada, and the world. Read more about OIRM here.
Stem Cell Network
The Stem Cell Network (SCN) is a national non-profit that supports stem cell and regenerative medicine research, training the next generation and outreach across Canada. SCN’s goal is to translate science from the lab to clinical applications, commercial products and public policy for the benefit of Canadians. SCN is supported by the Government of Canada and works in partnership with industry representatives, health charities, government and non-government organizations to build on Canada’s leadership in the sector. Since 2001, SCN has directed an investment of over $100M of strategic funding that has benefitted approximately 170 world-class research groups and 3,000 trainees and has catalyzed 19 clinical trials. Tomorrow’s health is here.
ThéCell is a non-profit network supported by the Fonds de recherche du Québec – Santé (FRQS), which is dedicated to furthering cell, gene and tissue therapies. ThéCell mobilizes researchers and resources for the development of new therapeutic approaches in regenerative medicine and accelerates the translation of discoveries stemming from Quebec laboratories toward clinical applications and treatments. The network acts as a catalyst to promote the collaboration between more than 100 researchers, clinicians and their teams (over 160 students and 50 research professionals) involved in key health research areas. ThéCell plays a central role in Quebec’s regenerative medicine landscape by strengthening scientific exchanges and promoting the emergence of new partnerships. Read more about ThéCell here.